All In Biotech

Drug Trial Radar · NCT06672393

A Study to Confirm Efficacy and Safety of HS-10374 for Moderate to Severe Plaque Psoriasis

A Multi-Center, Randomized, Double Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of HS-10374 in Adult Subjects With Moderate To Severe Plaque Psoriasis

Last checked: Nov 19, 2026Latest source record: Nov 4, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 375 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

375

Planned (sponsor's estimate)

Start

Nov 4, 2024

Primary completion

Oct 22, 2025

Study completion Jun 29, 2026

Sponsor

Lead sponsor
Hansoh BioMedical R&D CompanyIndustry
Sponsor type
Industry
First posted
Nov 4, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study has been designed to confirm the clinical efficacy and safety of HS-10374 in the treatment of moderate to severe plaque psoriasis.

Conditions

  • Psoriasis

Interventions

  • HS-10374 6mg tabletsDrug

    Specified dose of HS-10374 tablets administered orally QD on specified days

  • HS-10374-matched placebo tabletsDrug

    Specified dose of HS-10374-matched placebo tablets administered orally QD on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of patients achieving PASI 75 response at Week 16Time frame: Baseline to Week 16
  2. Proportion of patients achieving sPGA 0/1 with at least 2 points improvement from baseline at Week 16Time frame: Baseline to Week 16

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Huashan Hospital affiliated to Fudan University

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.